Arvato’s Post

We’re honored to have Greg Cathcart, 𝐒𝐞𝐧𝐢𝐨𝐫 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 at NNIT, share his expertise at the 𝟏𝟎𝐭𝐡 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦𝐚 𝐒𝐮𝐩𝐩𝐥𝐲 𝐂𝐡𝐚𝐢𝐧 & 𝐋𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐍𝐞𝐱𝐮𝐬. His session, “𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐓𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧 𝐭𝐨 𝐍𝐃𝐂‑𝟏𝟐,” brought clarity to one of the most important shifts in pharmaceutical supply chain standards. 🗣️ Greg explained how the move to NDC‑12 is transforming product identification—driving greater precision, compliance, and efficiency across logistics operations. He emphasized the importance of aligning organizational processes, technology, and regulatory frameworks to ensure readiness for this transition. We deeply appreciate Greg’s contribution, helping shape the conversation on how supply chain leaders can prepare for the future with resilience and innovation. #BioPharmaNexus #SupplyChain #Logistics #Philadelphia2026 #BiopharmaInnovation #HealthcareLeadership #PharmaLogistics #OperationalExcellence #FutureOfBiopharma #NDC12

Pleased to have 𝐆𝐫𝐞𝐠 𝐂𝐚𝐭𝐡𝐜𝐚𝐫𝐭 share his expertise on the NDC‑12 transition at the 𝟏𝟎𝐭𝐡 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦𝐚 𝐒𝐮𝐩𝐩𝐥𝐲 𝐂𝐡𝐚𝐢𝐧 & 𝐋𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐍𝐞𝐱𝐮𝐬 𝟐𝟎𝟐𝟔. His insights on driving precision, compliance, and operational readiness are invaluable for supply chain leaders navigating the future.

When I am asked what sets Biocair apart from our competitors; I could say that we are a white-glove, patient-centric, boutique GDP service provider specializing in time and temperature sensitive shipping and logistics. But that is a mouth full, and wouldn’t give anyone the true scope of what makes Biocair stand out amongst the crowd. I instead like to note what a true white-glove service experience should feel like. Not a hybrid model sold as white glove service that can cut costs and corners; but true door-to-door white-glove service. This is Biocair’s strength. Whether in the US, UK, EU, APAC, or elsewhere; our door-to-door white-glove logistics experience is driven for success by our global team ethos and every person involved from collection to delivery. Find out more below!

Eisai's $900M Leqembi forecast masks an immediate, mandated de-globalization of biopharma supply chains. The BIOSECURE Act became law on December 31, 2025, through the FY2026 National Defense Authorization Act. This legislation directly limits grants and contracts with designated "Biotechnology Companies of Concern," fundamentally reshaping procurement strategies for any entity receiving federal funds. The industry faces an immediate, non-negotiable imperative: identify and mitigate dependencies. Companies like Eisai project significant revenue growth, such as Leqembi's anticipated $900M. This growth must now occur within a dramatically re-calibrated global supply chain. Pharmaceutical Commerce noted on May 13, 2026, the Act's profound implications for pharma supply chains. Manufacturers must re-shore or near-shore critical materials and services. This process demands significant capital expenditure and operational overhaul. This is not a future scenario; it is current operational reality. Boards must prioritize comprehensive risk assessments across their entire value chain, beyond immediate Tier 1 suppliers. This requires identifying every component, raw material, and service provider potentially linked to entities proscribed by the Act. Strategic investments in alternative sourcing and manufacturing capabilities are essential for long-term market access and operational continuity. Full analysis on stratdeepview.com #Biopharma #SupplyChain #BIOSECUREAct #Geopolitics #PharmaStrategy

How is the off-patent medicines industry driving jobs and economic growth across Europe? 📊 As our companies invest in digitalisation, manufacturing innovation, and skills, a strong partnership with the EU is key to supporting sustainable growth and global competitiveness. At our Annual Conference 2026, we’ll explore how the off-patent sector contributes to affordable healthcare and how collaboration on high-quality employment and economic growth strengthens the EU economy and related policies. 💬 Panelists will share practical insights on building a competitive, innovative, and future-proof industrial base, including lessons from other regions using public support, fiscal incentives, and long-term strategies to attract pharmaceutical manufacturing. ➡️ Register here: https://buff.ly/HiPOBE9

Callan JMB has officially launched Atlas Complex by Callan JMB, a new infrastructure platform designed to support pharmaceutical onshoring and strengthen U.S. supply chains. Located in Marion, Alabama, this 150+ acre campus brings together production support, QA/QC, cold chain logistics, and distribution into one integrated environment. This launch comes at a critical moment. The White House and federal agencies have made it clear: the U.S. must reduce reliance on foreign pharmaceutical supply chains and accelerate domestic production of critical inputs like APIs. Today, only ~10% of APIs are produced domestically. Atlas Complex by Callan JMB is designed to help close that gap. This is not a real estate initiative—it’s a strategic expansion of how Callan JMB operates, embedding directly into the environments where onshoring is happening. https://lnkd.in/gD476Gh5 #Onshoring #Pharma #SupplyChain #Healthcare #Infrastructure #Policy #CallanJMB #Logistics

Pharmaceutical supply chains embrace digital networks to boost resilience and real-time visibility Pharmaceutical supply chains are being reshaped by a shift away from rigid, linear logistics towards digital supply networks that connect manufacturers, suppliers, logistics firms and healthcare providers in real time. The change matters because medicine delivery has become more complex, more global and more exposed to disruption, particularly where temperature-sensitive products must move through tightly controlled cold chains. The appeal of the model is visibility....

The next major challenge in pharma may not be medicine availability but supply chain resilience. Global disruptions are forcing pharmaceutical companies to rethink inventory planning, sourcing strategies, and operational visibility. From AI-driven supply chain tracking to stronger inventory buffers, resilience is becoming a competitive advantage rather than just an operational requirement. In fast-moving industries like healthcare, the most prepared organizations will lead. #SupplyChain #Pharma #Operations

🚀 GEODIS expands its pharmaceutical logistics capabilities in the UK 💊 We are pleased to announce the opening of our new temperature-controlled, #GDP-compliant pharmaceutical warehouse in Manchester, set to start action on June 1st, 2026. This state-of-the-art new facility will support both inventory management and cross-docking operations, reinforcing our commitment to the fast-growing Pharma & Healthcare sector in the UK and Ireland. What we can offer our customers to help foster their growth in this sector: 🔹 2,000 pallet positions for sensitive pharmaceutical products 🔹 Temperature-controlled zones (15–25°C and 2–8°C) with 24/7 monitoring 🔹 Strategic location near Manchester Airport and major transport corridors 🔹 Sustainable design with energy-efficient systems and waste-reduction initiatives With advanced monitoring, robust compliance standards, and seamless connectivity, we are ready to help pharmaceutical and biotech companies by delivering safe, efficient, and scalable logistics solutions! Learn more about this new facility here: https://bit.ly/4erVXcP #PharmaLogistics #Healthcare #ABetterWaytoDeliver

Another important step forward in ensuring the integrity and timely delivery of critical #healthcare products for our pharma & biotech customers! This new Manchester facility reflects our dedication to meeting the evolving needs of the pharma industry. 💊 Learn more ⬇️ #ABetterWaytoDeliver